Could CBD help control schizophrenia symptoms with fewer side effects?
NCT ID NCT02926859
First seen Feb 03, 2026 · Last updated May 08, 2026 · Updated 9 times
Summary
This study tests whether adding cannabidiol (CBD) to standard antipsychotic medication can help people with early schizophrenia manage their symptoms better and with fewer side effects. About 180 participants will receive either CBD or a placebo alongside their usual treatment for one year. The goal is to see if CBD helps people stay on treatment longer and improves their overall mental health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health
Mannheim, Baden-Wurttemberg, 68159, Germany
-
Department of Psychiatry und Psychotherapy, University Hospital Hamburg-Eppendorf
Hamburg, 20246, Germany
-
Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen
Aachen, North Rhine-Westphalia, 52074, Germany
-
Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte
Berlin, B, 10117, Germany
-
Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich
Munich, Bavaria, 80336, Germany
-
Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne
Cologne, North Rhine-Westphalia, 50924, Germany
Conditions
Explore the condition pages connected to this study.